OncoSil

OncoSil is a minimally invasive, intratumoural brachytherapy device that consists of microparticles loaded with the radioactive isotope phosphorus-32 (32P). It is designed for implantation directly into pancreatic tumours via endoscopic ultrasound-guided injection. The device emits targeted beta radiation over a short distance, enabling high-dose localised radiotherapy with minimal exposure to surrounding healthy tissue. The primary **mechanism of action** is the local emission of beta particles from phosphorus-32, causing direct DNA damage, inhibition of cancer cell division and proliferation, and eventual tumour shrinkage. OncoSil is primarily indicated for **locally advanced unresectable pancreatic cancer** in combination with gemcitabine-based chemotherapy. CE-marked in the EU and UK, OncoSil is supported by multiple clinical trials that showed promising local disease control and the potential to downstage unresectable disease to operable status. The developer and main manufacturer is OncoSil Medical.

Brand names

OncoSil

Other names

OncoSil 32POncoSil32POncoSil-32PPhosphorus-32 loaded microparticlePhosphorus32 loaded microparticlePhosphorus 32 loaded microparticleOncoSil™ device